Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 10:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 3097–3120 of 10,825 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Developmental Defect Clear all

Conditions: Pediatric Cancer, Sickle Cell Disease, Quality of Life, Depressive Symptoms, Coping Skills
Interventions: FOCUS; Behavioral
Lead sponsor: Georgia State University; Other
Eligibility: 12 Years to 18 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Small Cell Neuroendocrine Carcinoma, Prostate Cancer, Small Cell Carcinoma
Interventions: Apalutamide, Cetrelimab; Drug · Biological
Lead sponsor: Rahul Aggarwal; Other
Eligibility: 18 Years and older · Male only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Stargardt's Disease
Interventions: SAR422459; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 6 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 4
States / cities: Miami, Florida • Iowa City, Iowa • Portland, Oregon + 1 more

Conditions: Cystic Fibrosis, Chronic Bronchitis
Interventions: IV amikacin, PO azithromycin, IV ceftazidime, PO ciprofloxacin, IV meropenem, IV piperacillin-tazobactam, IV ticarcillin-clavulanate, IV tobramycin; Drug
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 14 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 8
States / cities: Iowa City, Iowa • St Louis, Missouri • Cincinnati, Ohio + 4 more

Conditions: Healthy Volunteer, Becker Muscular Dystrophy
Interventions: EDG-5506, Placebo; Drug
Lead sponsor: Edgewise Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 127 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Anemia, Sickle Cell
Interventions: Mindfulness-based Stress Reduction; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Male Infertility, Klinefelter's Syndrome, Y-chromosome Microdeletions
Interventions: 13-cis retinoic acid, Calcitriol; Drug
Lead sponsor: University of Washington; Other
Eligibility: 21 Years to 60 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Malformations, Multiple Abnormalies, Polydactyly
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: Not listed
Enrollment: 1,170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2016
U.S. locations: 3
States / cities: Los Angeles, California • Bethesda, Maryland • Greenwood, South Carolina

Conditions: Alcohol Drinking, Sex Behavior, Men
Interventions: Alcohol, Placebo (non-alcoholic beverage); Drug · Other
Lead sponsor: Syracuse University; Other
Eligibility: 21 Years to 50 Years · Male only
Enrollment: 260 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 3
States / cities: Boston, Massachusetts • Syracuse, New York • Vermillion, South Dakota

Conditions: Skin Condition, Skin Diseases, Skin Lesion, Skin Abnormalities, Skin Cancer
Interventions: VIO Imaging; Device
Lead sponsor: Enspectra Health; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Merced, California • Walnut Creek, California

Conditions: Laxity; Skin
Interventions: MCD; Device
Lead sponsor: Cytrellis Biosystems, Inc.; Industry
Eligibility: 40 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 5
States / cities: Sacramento, California • Miami, Florida • New York, New York + 2 more

Conditions: Skin Laxity of Abdomen, Thighs, Chest, Back, and Neck
Interventions: Absorbable sutures; Device
Lead sponsor: Medtronic - MITG; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Diabetes Mellitus (DM)
Interventions: Foot exercise, Shoulder exercise; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 40 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Congenital Heart Disease, Tetrology of Fallot, RVOT Anomaly, Pulmonary Regurgitation
Interventions: Harmony TPV System; Device
Lead sponsor: Medtronic Heart Valves; Industry
Eligibility: Not listed
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2031
U.S. locations: 9
States / cities: Los Angeles, California • Palo Alto, California • New Haven, Connecticut + 6 more

Conditions: Chronic Kidney Disease
Interventions: Not listed
Lead sponsor: Baptist Health South Florida; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Cystic Fibrosis
Interventions: Immediate Oral Antibiotics, Tailored Treatment: Oral Antibiotics only if Additional Treatment needed; Other
Lead sponsor: University of Washington, the Collaborative Health Studies Coordinating Center; Other
Eligibility: 3 Years to 18 Years
Enrollment: 430 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 31
States / cities: Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 27 more

Conditions: Pruritus, Atopic Dermatitis
Interventions: difelikefalin 0.25 mg, difelikefalin 0.5 mg, TCS Cream, Placebo, Vehicle Cream; Drug
Lead sponsor: Cara Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 61
States / cities: Scottsdale, Arizona • Fort Smith, Arkansas • Rogers, Arkansas + 56 more

Conditions: Atopic Dermatitis
Interventions: ruxolitinib cream; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 30
States / cities: Fountain Valley, California • Long Beach, California • Washington D.C., District of Columbia + 26 more

Conditions: Cystic Fibrosis
Interventions: VX-371 + HS, Hypertonic saline, Placebo, Orkambi, VX-371; Drug
Lead sponsor: Parion Sciences; Industry
Eligibility: 12 Years and older
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 30
States / cities: Little Rock, Arkansas • Oakland, California • Gainesville, Florida + 27 more

Conditions: Heart Defects, Congenital
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Up to 12 Months
Enrollment: 1,610 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Berkeley, California

Conditions: Distal Renal Tubular Acidosis
Interventions: ADV7103, Placebo; Drug
Lead sponsor: Advicenne Pharma; Industry
Eligibility: 6 Months to 65 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 6
States / cities: Aurora, Colorado • Tampa, Florida • Atlanta, Georgia + 3 more

Conditions: Metachromatic Leukodystrophy
Interventions: Not listed
Lead sponsor: National Organization for Rare Disorders; Other
Eligibility: Not listed
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Danbury, Connecticut

Conditions: Down Syndrome
Interventions: Babble Boot Camp; Behavioral
Lead sponsor: Arizona State University; Other
Eligibility: 0 Months to 12 Months
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Leukemia
Interventions: asparaginase, cytarabine, daunorubicin hydrochloride, etoposide, gemtuzumab ozogamicin, mitoxantrone hydrochloride; Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 29 Years
Enrollment: 1,070 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2020
U.S. locations: 178
States / cities: Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 141 more

Search by objective public record fields.

FOCUS for Pediatric Sickle Cell Disease and Cancer

Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer

Phase I/IIA Study of SAR422459 in Participants With Stargardt's Macular Degeneration

Standard vs. Biofilm Susceptibility Testing in Cystic Fibrosis (CF)

A Study to Assess Safety, Tolerability, and PK of EDG-5506 in Healthy Volunteers and Becker Muscular Dystrophy Adults

MBSR for Pain Catastrophizing in SCD

RA-2 13-cis Retinoic Acid (Isotretinoin)

Phenotype and Etiology of Pallister-Hall Syndrome

Alcohol and Implicit Process in Sexual Risk Behavior in MSM

VIO Imaging for Skin Tissue Assessment (VISTA)

Pivotal Study to Evaluate the Safety and Efficacy of a Micro-coring Device Treating Moderate to Severe Facial Wrinkles

Suture Granuloma in Body Contouring Surgery

Metatarsal Phalangeal Joint Deformity Progression - R01

The Medtronic Harmony™ Transcatheter Pulmonary Valve Clinical Study

Ultrasound to Predict Steal-Syndrome After Arteriovenous-Fistula Creation (UPSAC - Trial)

Streamlined Treatment of Pulmonary Exacerbations in Pediatrics

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis

The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance.

A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation

Genetic and Nutritional Causes of Heart Birth Defects

Study Evaluating Subjects With Distal Renal Tubular Acidosis

The Natural History of Metachromatic Leukodystrophy Study (HOME Study)

Proactive Speech and Language Intervention for Infants With Down Syndrome

Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia